Overall, our study offers novel insights into the molecular mechanisms underlying thyroid cancer progression and drug resistance, paving the way for the development of more effective therapeutic strategies for patients with BRAF-mutated thyroid cancer and potentially other malignancies. The gene discussed is BRAF; the disease is thyroid gland carcinoma.